Publications

For up-to-date publications, please refer to Dr. Testai’s publications on PubMed

1. Venera GD, Testai FD, Pena C, Lacorazza HD, Biscoglio De Jimenez Bonino, M. J. Involvement of histidine 134 in the binding of alpha-bungarotoxin to the nicotinic acetylcholine receptor. Neurochem Int. 1997;31(1):151-157. doi: S0197-0186(96)00063-0 [pii].

2. Testai FD, Venera GD, Pena C, de Jimenez Bonino, M. J. Histidine 186 of the nicotinic acetylcholine receptor alpha subunit requires the presence of the 192-193 disulfide bridge to interact with alpha-bungarotoxin. Neurochem Int. 2000;36(1):27-33. doi: S0197018699000996 [pii].

3. Cortez LM, del Canto SG, Testai FD, Biscoglio de Jimenez Bonino, M. J. Conotoxin MI inhibits the alpha-delta acetylcholine binding site of the torpedo marmorata receptor. Biochem Biophys Res Commun. 2002;295(4):791-795. doi: S0006291X02007581 [pii].

4. Kilkus J, Goswami R, Testai FD, Dawson G. Ceramide in rafts (detergent-insoluble fraction) mediates cell death in neurotumor cell lines. J Neurosci Res. 2003;72(1):65-75. doi: 10.1002/jnr.10549 [doi].

5. Testai FD, Landek MA, Dawson G. Regulation of sphingomyelinases in cells of the oligodendrocyte lineage. J Neurosci Res. 2004;75(1):66-74. doi: 10.1002/jnr.10816 [doi].

6. Testai FD, Landek MA, Goswami R, Ahmed M, Dawson G. Acid sphingomyelinase and inhibition by phosphate ion: Role of inhibition by phosphatidyl-myo-inositol 3,4,5-triphosphate in oligodendrocyte cell signaling. J Neurochem. 2004;89(3):636-644. doi: 10.1046/j.1471-4159.2004.02374.x [doi].

7. Kilkus JP, Goswami R, Dawson SA, et al. Differential regulation of sphingomyelin synthesis and catabolism in oligodendrocytes and neurons. J Neurochem. 2008;106(4):1745-1757. doi: 10.1111/j.1471-4159.2008.05490.x [doi].

8. Testai FD, Aiyagari V. Acute hemorrhagic stroke pathophysiology and medical interventions: Blood pressure control, management of anticoagulant-associated brain hemorrhage and general management principles. Neurol Clin. 2008;26(4):ix. doi: 10.1016/j.ncl.2008.06.001 [doi].

9. Aiyagari V, Testai FD. Correction of coagulopathy in warfarin associated cerebral hemorrhage. Curr Opin Crit Care. 2009;15(2):87-92. doi: 10.1097/MCC.0b013e3283269e4d [doi].

10. Qin J, Testai FD, Dawson S, Kilkus J, Dawson G. Oxidized phosphatidylcholine formation and action in oligodendrocytes. J Neurochem. 2009;110(5):1388-1399. doi: 10.1111/j.1471-4159.2009.06231.x [doi].

11. Testai FD, Gorelick PB. Inherited metabolic disorders and stroke part 1: Fabry disease and mitochondrial myopathy, encephalopathy, lactic acidosis, and strokelike episodes. Arch Neurol. 2010;67(1):19-24. doi: 10.1001/archneurol.2009.309 [doi].

12. Testai FD, Gorelick PB. Inherited metabolic disorders and stroke part 2: Homocystinuria, organic acidurias, and urea cycle disorders. Arch Neurol. 2010;67(2):148-153. doi: 10.1001/archneurol.2009.333 [doi].

13. Testai FD, Cursio JF, Gorelick PB. Effect of sex on outcome after recurrent stroke in african americans: Results from the african american antiplatelet stroke prevention study. J Stroke Cerebrovasc Dis. 2010;19(4):321-325. doi: 10.1016/j.jstrokecerebrovasdis.2009.05.008 [doi].

14. Testai FD, Gorelick PB. New approaches to stroke prevention in atrial fibrillation. Curr Treat Options Cardiovasc Med. 2010;12(3):261-273. doi: 10.1007/s11936-010-0071-z [doi].

15. Testai FD, Gorelick PB. An unusual cause of vertebral artery dissection: Esophagogastroduodenoscopy. Stroke Res Treat. 2010;2010:10.4061/2010/915484. doi: 10.4061/2010/915484 [doi].

16. Nair A, Testai FD. Recurrent posterior reversible encephalopathy syndrome in a sickle cell patient. J Natl Med Assoc. 2011;103(2):170-172. doi: S0027-9684(15)30267-4 [pii].

17. Testai FD, Aiyagari V, Hillmann M, Amin-Hanjani S, Dawson G, Gorelick P. Proof of concept: Endogenous antiangiogenic factors predict the occurrence of symptomatic vasospasm post subarachnoid hemorrhage. Neurocrit Care. 2011;15(3):416-420. doi: 10.1007/s12028-011-9559-y [doi].

18. Muqtadar H, Testai FD. Single gene disorders associated with stroke: A review and update on treatment options. Curr Treat Options Cardiovasc Med. 2012;14(3):288-297. doi: 10.1007/s11936-012-0179-4 [doi].

19. Testai FD, Hillmann M, Amin-Hanjani S, et al. Changes in the cerebrospinal fluid ceramide profile after subarachnoid hemorrhage. Stroke. 2012;43(8):2066-2070. doi: 10.1161/STROKEAHA.112.650390 [doi].

20. Testai FD. Intravenous thrombolysis in a stroke patient taking dabigatran. J Stroke Cerebrovasc Dis. 2013;22(6):894. doi: 10.1016/j.jstrokecerebrovasdis.2012.06.017 [doi].

21. Muqtadar H, Testai FD, Gorelick PB. The dementia of cardiac disease. Curr Cardiol Rep. 2012;14(6):732-740. doi: 10.1007/s11886-012-0304-8 [doi].

22. Woo D, Rosand J, Kidwell C, et al. The ethnic/racial variations of intracerebral hemorrhage (ERICH) study protocol. Stroke. 2013;44(10):120. doi: 10.1161/STROKEAHA.113.002332 [doi].

23. Testai FD, Kilkus JP, Berdyshev E, Gorshkova I, Natarajan V, Dawson G. Multiple sphingolipid abnormalities following cerebral microendothelial hypoxia. J Neurochem. 2014;131(4):530-540. doi: 10.1111/jnc.12836 [doi].

24. Tobin MK, Bonds JA, Minshall RD, Pelligrino DA, Testai FD, Lazarov O. Neurogenesis and inflammation after ischemic stroke: What is known and where we go from here. J Cereb Blood Flow Metab. 2014;34(10):1573-1584. doi: 10.1038/jcbfm.2014.130 [doi].

25. Aiyagari V, Pandey DK, Testai FD, et al. A prototype worldwide survey of diagnostic and treatment modalities for stroke. J Stroke Cerebrovasc Dis. 2015;24(2):290-296. doi: 10.1016/j.jstrokecerebrovasdis.2014.08.002 [doi].

26. Li W, Shafi N, Periakaruppan R, Valyi-Nagy T, Groth J, Testai FD. Cerebral aspergillosis in a diabetic patient leading to cerebral artery occlusion and ischemic stroke: A case report and literature review. J Stroke Cerebrovasc Dis. 2015;24(1):39. doi: 10.1016/j.jstrokecerebrovasdis.2014.08.025 [doi].

27. Testai FD, Xu HL, Kilkus J, et al. Changes in the metabolism of sphingolipids after subarachnoid hemorrhage. J Neurosci Res. 2015;93(5):796-805. doi: 10.1002/jnr.23542 [doi].

28. Xu HL, Pelligrino DA, Paisansathan C, Testai FD. Protective role of fingolimod (FTY720) in rats subjected to subarachnoid hemorrhage. J Neuroinflammation. 2015;12:7. doi: 10.1186/s12974-015-0234-7 [doi].

29. Xu H, Testai FD, Valyi-Nagy T, et al. VAP-1 blockade prevents subarachnoid hemorrhage-associated cerebrovascular dilating dysfunction via repression of a neutrophil recruitment-related mechanism. Brain Res. 2015;1603:141-149. doi: 10.1016/j.brainres.2015.01.047 [doi].

30. Boullerne AI, Skias D, Hartman EM, et al. A single-nucleotide polymorphism in serine-threonine kinase 11, the gene encoding liver kinase B1, is a risk factor for multiple sclerosis. ASN Neuro. 2015;7(1):Feb. doi: 10.1177/1759091415568914 [doi].

31. Kord Valeshabad A, Wanek J, Mukarram F, Zelkha R, Testai FD, Shahidi M. Feasibility of assessment of conjunctival microvascular hemodynamics in unilateral ischemic stroke. Microvasc Res. 2015;100:4-8. doi: 10.1016/j.mvr.2015.04.007 [doi].

32. Changyaleket B, Xu H, Vetri F, et al. Intracerebroventricular application of S100B selectively impairs pial arteriolar dilating function in rats. Brain Res. 2016;1634:171-178. doi: S0006-8993(15)01000-8 [pii].

33. Woo D, Kruger AJ, Sekar P, et al. Incontinence and gait disturbance after intraventricular extension of intracerebral hemorrhage. Neurology. 2016;86(10):905-911. doi: 10.1212/WNL.0000000000002449 [doi].

34. Vargas A, Gorelick PB, Testai FD. Progressive central nervous system vasculopathy in sarcoidosis: A case report. J Neurol Sci. 2016;362:153-154. doi: 10.1016/j.jns.2016.01.050 [doi].

35. Vargas A, Dixit KS, Quigley JG, Testai FD. Spinal cord and cranial bing-neel syndrome complicated by cerebral ischemia: A case report. J Neurol Sci. 2016;366:44-46. doi: S0022-510X(16)30239-8 [pii].

36. Koch S, Elkind MS, Testai FD, et al. Racial-ethnic disparities in acute blood pressure after intracerebral hemorrhage. Neurology. 2016;87(8):786-791. doi: 10.1212/WNL.0000000000002962 [doi].

37. Li W, Xu H, Testai FD. Mechanism of action and clinical potential of fingolimod for the treatment of stroke. Front Neurol. 2016;7:139. doi: 10.3389/fneur.2016.00139 [doi].

38. Testai FD. The relevance of atrial fibrillation in stroke prevention. Lancet Neurol. 2017;16(4):253-255. doi: S1474-4422(17)30016-9 [pii].

39. Cruz ML, Farooq S, Testai FD. Neurological and neurosurgical emergencies in patients with hematological disorders. Curr Neurol Neurosci Rep. 2017;17(3):z. doi: 10.1007/s11910-017-0728-z [doi].

40. Gorelick PB, Furie KL, Iadecola C, et al. Defining optimal brain health in adults: A presidential advisory from the american heart association/american stroke association. Stroke. 2017;48(10):e303. doi: 10.1161/STR.0000000000000148 [doi].

41. Biffi A, Kuramatsu JB, Leasure A, et al. Oral anticoagulation and functional outcome after intracerebral hemorrhage. Ann Neurol. 2017;82(5):755-765. doi: 10.1002/ana.25079 [doi].

42. Geraghty JR, Testai FD. Delayed cerebral ischemia after subarachnoid hemorrhage: Beyond vasospasm and towards a multifactorial pathophysiology. Curr Atheroscler Rep. 2017;19(12):x. doi: 10.1007/s11883-017-0690-x [doi].

43. Boehme AK, Comeau ME, Langefeld CD, et al. Systemic inflammatory response syndrome, infection, and outcome in intracerebral hemorrhage. Neurol Neuroimmunol Neuroinflamm. 2017;5(2):e428. doi: 10.1212/NXI.0000000000000428 [doi].

44. MacIntosh PW, Lin AY, Kim JS, Testai FD, Moss HE. Cerebral venous thrombosis with papilloedema secondary to skull base plasmacytoma. Neuroophthalmology. 2017;41(5):284-286. doi: 10.1080/01658107.2017.1308520 [doi].

45. Chen CJ, Ding D, Buell TJ, et al. Restarting antiplatelet therapy after spontaneous intracerebral hemorrhage: Functional outcomes. Neurology. 2018;91(1):e36. doi: 10.1212/WNL.0000000000005742 [doi].

46. Rodriguez-Torres A, Murphy M, Kourkoulis C, et al. Hypertension and intracerebral hemorrhage recurrence among white, black, and hispanic individuals. Neurology. 2018;91(1):e44. doi: 10.1212/WNL.0000000000005729 [doi].

47. Ormseth CH, Falcone GJ, Jasak SD, et al. Minority patients are less likely to undergo withdrawal of care after spontaneous intracerebral hemorrhage. Neurocrit Care. 2018. doi: 10.1007/s12028-018-0554-4 [doi].

48. Marini S, Lena UK, Crawford KM, et al. Comparison of genetic and self-identified ancestry in modeling intracerebral hemorrhage risk. Front Neurol. 2018;9:514. doi: 10.3389/fneur.2018.00514 [doi].

49. Trifan G, Shafi N, Testai FD. Implications of janus kinase 2 mutation in embolic stroke of unknown source. J Stroke Cerebrovasc Dis. 2018;27(10):2572-2578. doi: S1052-3057(18)30301-X [pii].

50. Murphy MP, Kuramatsu JB, Leasure A, et al. Cardioembolic stroke risk and recovery after anticoagulation-related intracerebral hemorrhage. Stroke. 2018;49(11):2652-2658. doi: 10.1161/STROKEAHA.118.021799 [doi].

51. Angulo M, Springer L, Behbahani M, et al. Improving ventriculostomy management: Risk and cost reduction through a multi-disciplinary approach. World Neurosurg. 2018. doi: S1878-8750(18)32572-5 [pii].